HTA-Information Service Rapid Reviews

Since 2023, the Austrian Institute for Health Technology Assessment (AIHTA) has been supporting decisions made by the umbrella organization of Austrian social insurance funds (DVSV) and decisions made by Austrian hospital operators with short evidence syntheses. The aim is to underpin these decisions on medical services with evidence. The best available evidence from current scientific studies is summarized in the form of rapid reviews.

HTA -Information Service No. 015
Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets

HTA-Information Service Review No. 014
Skin cancer prevention: Guideline recommendations for primary and secondary prevention

HTA-Information Service Review No. 013
CAR-based immunotherapy with a focus on CAR-NK cells

HTA-Information Service Review No. 012
Use of telepathology for intraoperative frozen section examination

HTA-Information Service Review No. 011
Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023

HTA -Information Service Review No. 010
Biomarkers in Parkinson's Disease

HTA -Information Service Review No. 009
Liposuction for the removal of subcutaneous (large) lipomas

HTA-Information Service Rapid Review No. 008
Endovenous laser therapy for varicose veins in the lower extremities

HTA-Information Service Rapid Review No. 007
Autologous fat grafting in osteoarthritis

HTA-Information Service Rapid Review No. 006
Myopia control spectacle lenses for children and adolescents

HTA-Information Service Rapid Review No. 005
Robot-assisted rehabilitation for incomplete spinal cord injury

HTA-Information Service Rapid Review No. 004
Biomarkers in Alzheimer's Disease

HTA-Information Service Rapid Review No. 003
Radiofrequency denervation for chronic lumbar or cervical spine pain

HTA-Information Service Rapid Review No. 002 
Extracorporeal shock wave therapy for orthopaedic indications

HTA-Information Service Rapid Review No. 001 
iv Immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss